Search research articles
Contact Us
Filters
Showing results (481-490 of 596) with videos related to
Page
of 60
Sort By:
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
May 25, 2013
Analysis of left ventricular mass in untreated men and in men treated with agalsidase-β: data from the Fabry Registry
Dominique P Germain, Frank Weidemann, Ademola Abiose, et al.
Journal of the American Heart Association
|
April 24, 2014
Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial
Jonathan P Piccini, Anne S Hellkamp, Yuliya Lokhnygina, et al.
JACC. Cardiovascular Interventions
|
August 20, 2016
Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial
Matthew W Sherwood, Derek D Cyr, W Schuyler Jones, et al.
Journal of the American College of Cardiology
|
February 7, 2024
Bleeding Outcomes in Patients Treated With Asundexian in Phase II Trials
John W Eikelboom, Hardi Mundl, John H Alexander, et al.
European Heart Journal
|
March 25, 2014
Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial
Jonathan P Piccini, Jyotsna Garg, Manesh R Patel, et al.
Circulation
|
December 6, 2012
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts
Jonathan P Piccini, Susanna R Stevens, YuChiao Chang, et al.
European Heart Journal
|
October 18, 2013
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial
Kenneth W Mahaffey, Susanna R Stevens, Harvey D White, et al.
American Heart Journal
|
February 11, 2021
Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AF
Vanessa Blumer, Manuel Rivera, Ramón Corbalán, et al.
The New England Journal of Medicine
|
August 12, 2011
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Manesh R Patel, Kenneth W Mahaffey, Jyotsna Garg, et al.
Circulation
|
September 11, 2013
Response to letter regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts"
Jonathan P Piccini, Susanna R Stevens, Yuchiao Chang, et al.
Page
of 60
Search research articles
Search
Showing results (481-490 of 596) with videos related to
Sort By:
Page
of 60
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
May 25, 2013
Analysis of left ventricular mass in untreated men and in men treated with agalsidase-β: data from the Fabry Registry
Dominique P Germain, Frank Weidemann, Ademola Abiose, et al.
Journal of the American Heart Association
|
April 24, 2014
Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial
Jonathan P Piccini, Anne S Hellkamp, Yuliya Lokhnygina, et al.
JACC. Cardiovascular Interventions
|
August 20, 2016
Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial
Matthew W Sherwood, Derek D Cyr, W Schuyler Jones, et al.
Journal of the American College of Cardiology
|
February 7, 2024
Bleeding Outcomes in Patients Treated With Asundexian in Phase II Trials
John W Eikelboom, Hardi Mundl, John H Alexander, et al.
European Heart Journal
|
March 25, 2014
Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial
Jonathan P Piccini, Jyotsna Garg, Manesh R Patel, et al.
Circulation
|
December 6, 2012
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts
Jonathan P Piccini, Susanna R Stevens, YuChiao Chang, et al.
European Heart Journal
|
October 18, 2013
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial
Kenneth W Mahaffey, Susanna R Stevens, Harvey D White, et al.
American Heart Journal
|
February 11, 2021
Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AF
Vanessa Blumer, Manuel Rivera, Ramón Corbalán, et al.
The New England Journal of Medicine
|
August 12, 2011
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Manesh R Patel, Kenneth W Mahaffey, Jyotsna Garg, et al.
Circulation
|
September 11, 2013
Response to letter regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts"
Jonathan P Piccini, Susanna R Stevens, Yuchiao Chang, et al.
Page
of 60